| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023573267 |
| P356 | DOI | 10.1007/S12094-007-0083-7 |
| P698 | PubMed publication ID | 17652058 |
| P2093 | author name string | B Ojeda | |
| A Poveda | |||
| R Salazar | |||
| J Cassinello | |||
| J García-Foncillas | |||
| M J Rubio | |||
| A Oaknin | |||
| J A Arranz | |||
| A González Martín | |||
| C Mendiola | |||
| J M del Campo | |||
| P2860 | cites work | Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma | Q60685709 |
| Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds | Q68927282 | ||
| Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study | Q69900723 | ||
| Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience | Q70530661 | ||
| Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study | Q71975328 | ||
| Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer | Q73443071 | ||
| Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments] | Q73948160 | ||
| Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer | Q77321076 | ||
| Markedly elevated levels of vascular endothelial growth factor in malignant ascites | Q77914895 | ||
| Intraperitoneal chemotherapy in ovarian cancer remains experimental | Q79157119 | ||
| Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial | Q79158185 | ||
| Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study | Q80396730 | ||
| Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design | Q80396736 | ||
| Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer | Q24244876 | ||
| Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 | ||
| Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study | Q33330626 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study | Q33341733 | ||
| Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel | Q33503973 | ||
| Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin | Q34604181 | ||
| Anti-epidermal growth factor receptor drugs in cancer therapy | Q34660837 | ||
| Relapsed ovarian cancer: challenges and management strategies for a chronic disease | Q34905674 | ||
| Intraperitoneal antineoplastic drug delivery: rationale and results | Q35121705 | ||
| Optimal sequencing in the treatment of recurrent ovarian cancer | Q35226268 | ||
| Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy | Q36040207 | ||
| Monoclonal antibody therapy of ovarian cancer | Q36066157 | ||
| Is there still a role for hormonal therapy? | Q36338807 | ||
| Ovarian cancer: is the news good enough? | Q36338812 | ||
| Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma | Q36621710 | ||
| Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study | Q36836814 | ||
| Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin | Q37649484 | ||
| The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model | Q40533881 | ||
| Second-line chemotherapy for recurrent carcinoma of the ovary. | Q40708166 | ||
| Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. | Q40959114 | ||
| Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. | Q42500788 | ||
| Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients | Q43567478 | ||
| Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan | Q43675453 | ||
| Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders | Q44150789 | ||
| Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy | Q44608414 | ||
| Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma | Q44695865 | ||
| Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. | Q46387517 | ||
| Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study | Q46505904 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. | Q53227029 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. | Q53300225 | ||
| Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. | Q53301937 | ||
| Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. | Q53495072 | ||
| Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. | Q54061091 | ||
| Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer | Q54169111 | ||
| Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population | Q54272955 | ||
| A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer | Q57975564 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 443-451 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Clinical and Translational Oncology | Q15754324 |
| P1476 | title | Update in the management of ovarian and cervical carcinoma | |
| P478 | volume | 9 |
| Q42364442 | DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy |
| Q33787894 | Drug delivery systems for intraperitoneal therapy |
| Q35869447 | Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors |
| Q88718086 | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| Q36685405 | Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells. |
| Q53249637 | Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. |
Search more.